Controlling MYC’s hyperactivity with a peptide compound 8 January 2024 | By Drug Target Review A novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development.
Delivering a human monoclonal IgG1 antibody to the brain 5 January 2024 | By Drug Target Review Adding a biodegradable polymer at the hinge and near hinge regions of trastuzumab enabled its movement across the blood-brain barrier.
The loading mechanism of bacteria injectisomes is now understood 5 January 2024 | By Drug Target Review Proximity labelling and single-particle tracking demonstrated that effectors in bacteria bind to mobile injectisome components.
Potential of precision diagnostics for gestational diabetes mellitus 4 January 2024 | By Drug Target Review Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Discovery enables further investigation into new ligases 4 January 2024 | By Drug Target Review Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
New technology to effectively regulate gene expression 3 January 2024 | By Drug Target Review A new strategy enables researchers to be more precise in the control of gene expression of a therapeutic protein.
New insights into the functions of inflammasomes 3 January 2024 | By Drug Target Review For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
Targets for pancreatic cancer treatment found 2 January 2024 | By Drug Target Review Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
Mechanism discovered that enables TB persistence in humans 2 January 2024 | By Drug Target Review One gene involved in the production of iron-sulphur clusters may be crucial for the persistence of Mycobacterium tuberculosis.
Novel class of antibodies can neutralise multiple strains of flu virus 22 December 2023 | By Drug Target Review The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
How gene regulatory networks maintain FLT3-ITD mutated AML 22 December 2023 | By Drug Target Review Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
New insights about the development of hematopoietic stem cells 21 December 2023 | By Drug Target Review Understanding the involvement of Nod1 in the development of blood stem cells could greatly improve blood disorder treatments.
Model for spinal muscular atrophy using human iPSCs 21 December 2023 | By Drug Target Review A 2D neuromuscular junction model enables high-throughput screening to discover new treatments for neuromuscular diseases.
How pathological alpha synuclein causes neuron death 20 December 2023 | By Drug Target Review A new finding that pathological alpha-synuclein causes cells to increase protein synthesis suggests new targets for treating PD.
AI system produces binding proteins using limited target information 20 December 2023 | By Drug Target Review New software can make protein molecules that bind with high affinity and specificity to many biomarkers, including human hormones.
